What the review examined
MASLD is a chronic liver disease closely associated with obesity and insulin resistance. Researchers are interested in polyamines for their potential role in the metabolic and inflammatory pathways involved in this disease. However, this biological plausibility is not evidence of clinical usefulness.
The review brings together nine observational studies, including more than 1,400 participants in clinical cohorts, along with transcriptomic analyses from public databases. The literature search covers publications available through April 2026. The authors conducted a qualitative synthesis, rather than calculating a pooled estimate of the association.
Associations differ by molecule and sample type
In one study, a higher concentration of putrescine in the liver, accompanied by an increase in ornithine decarboxylase, was associated with greater histological severity and more liver cell damage. This finding does not demonstrate that putrescine causes this damage.
Conversely, some studies associated lower spermidine concentrations in circulating samples or stool with more severe disease. Changes in polyamine-related molecular pathways and microbially derived polyamines were also associated with severity.
These findings therefore do not describe a uniform rise or fall in polyamines. The molecule measured, sample type, analytical method and approach to assessing the disease differed between studies, limiting comparisons.
Why this is not enough to make a test
An association with severity does not guarantee that a measurement can correctly classify patients. None of the included studies established diagnostic performance measures such as sensitivity, specificity, predefined thresholds or external validation.
The practical question therefore remains open: would these measurements provide additional information beyond already established non-invasive tools? The authors call for prospective, longitudinal, multicentre studies using standardised methods to find out.
What this means for spermidine
Observing less spermidine in some patients with more severe disease does not mean that taking it improves their condition. This review does not examine supplementation trials and cannot determine the direction of the observed relationship. It identifies avenues for research, not a treatment.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. The studies are observational and heterogeneous, with no demonstration of causality or diagnostic validation. The abstract does not specify follow-up duration. Funding and conflicts of interest were not verified.
What we can take away
Polyamines are candidate biomarkers of MASLD severity, not validated tests. This review does not justify spermidine supplementation.
Sources and provenance
- Polyamine Dysregulation in Metabolic Dysfunction-associated Steatotic Liver Disease: a Systematic Review of Human Observational Evidence.
Source date: 2026-11-11.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté


